Downregulation of Dickkopf-3, a Wnt antagonist elevated in Alzheimer's disease, restores synapse integrity and memory in a disease mouse model.
Nuria Martin-FloresMarina PodpolnyFaye McLeodIsaac WorkmanKaren CrawfordDobril IvanovGanna LeonenkoValentina Escott-PricePatricia C SalinasPublished in: eLife (2024)
Increasing evidence supports a role for deficient Wnt signaling in Alzheimer's disease (AD). Studies reveal that the secreted Wnt antagonist Dickkopf-3 (DKK3) colocalizes to amyloid plaques in AD patients. Here, we investigate the contribution of DKK3 to synapse integrity in healthy and AD brains. Our findings show that DKK3 expression is upregulated in the brains of AD subjects and that DKK3 protein levels increase at early stages in the disease. In hAPP-J20 and hAPP NL-G-F/NL-G-F mouse AD models, extracellular DKK3 levels are increased and DKK3 accumulates at dystrophic neuronal processes around plaques. Functionally, DKK3 triggers the loss of excitatory synapses through blockade of the Wnt/GSK3β signaling with a concomitant increase in inhibitory synapses via activation of the Wnt/JNK pathway. In contrast, DKK3 knockdown restores synapse number and memory in hAPP-J20 mice. Collectively, our findings identify DKK3 as a novel driver of synaptic defects and memory impairment in AD.
Keyphrases
- cell proliferation
- stem cells
- mouse model
- signaling pathway
- working memory
- newly diagnosed
- magnetic resonance
- metabolic syndrome
- gene expression
- type diabetes
- adipose tissue
- ejection fraction
- cognitive decline
- computed tomography
- single cell
- chronic kidney disease
- prognostic factors
- magnetic resonance imaging
- dna methylation
- mild cognitive impairment
- patient reported outcomes
- insulin resistance
- induced apoptosis